Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Clinical evidence

AL102-504

11 evidence topics · 1 source

Objective
Location and study date
Registry status, dates, and site
Study characteristicQuoted record
Protocol number“AL102-504”
Sponsor“Immunome, Inc.”
Overall status“Completed”
Study start (actual)“2025-02-25”
Primary completion (actual)“2025-03-11”
Study completion (actual)“2025-03-26”
Last update posted“2025-09-26”
Site“Frontage Laboratories, Inc.”; “Secaucus”
Study design
Registry design fields
Study characteristicQuoted record
Phase“Phase 1”
Intervention model“Single Group Assignment”
Masking“None (Open Label)”
Primary purpose“Other”
Eligibility criteria
Treatment
Study outcomes
Rationale for using mass balance recovery as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Study characteristicQuoted record
Enrollment (actual)“6”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AL102-504 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-03-11, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the routes of elimination and the metabolite profile of varegacestat are unknown from public sources.
  • The study enrolled 6 healthy men aged 18 to 55 years and gave a single dose of approximately 100 µCi of [14C]varegacestat, so it provides no data in women, in patients with desmoid tumors, or at steady state.